Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation. 1981;64:667-668

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Detre, K. M.
Right arrow Articles by Mantel, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Detre, K. M.
Right arrow Articles by Mantel, N.

Circulation, Vol 64, 667-668, Copyright © 1981 by American Heart Association

ARTICLES

Are clinical trials in coronary heart disease oversold or undersold?

KM Detre, J Ware and N Mantel

Randomized clinical trials constitute the formal experiments in therapeutics. Many such trials in coronary heart disease have terminated inconclusively or in controversy. In this editorial, we analyze some of the methodologic issues that may lead to controversy; the main reason for the low success rate may lie in insufficient understanding of the complex biology of the disease and in failure to select the appropriate models for therapy. We argue that these difficulties only strengthen the need for the rigorous experimental approach to the evaluation of therapies for coronary heart disease.




Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1981 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.